A Phase 1/2 Study of Osimertinib in Combination With Gefitinib in EGFR Inhibitor naive Advanced EGFR Mutant Lung Cancer
Latest Information Update: 17 May 2024
At a glance
- Drugs Gefitinib (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 May 2024 Planned End Date changed from 1 Apr 2025 to 1 Apr 2026.
- 13 May 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Apr 2025.
- 09 May 2023 Planned End Date changed from 1 Apr 2024 to 1 Apr 2025.